The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.

Karthick VishwanathanPaul A DickinsonKaren SoKaren ThomasYuh-Min ChenJavier De Castro CarpeñoAnne-Marie C DingemansHye Ryun KimJoo-Hang KimMatthew G KrebsJames Chih-Hsin YangKhanh BuiDoris WeilertR Donald Harvey

Published in: British journal of clinical pharmacology (2018)

Osimertinib can be co-administered with CYP3A4 inhibitors, but strong CYP3A inducers should be avoided if possible.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
epidermal growth factor receptor
mycobacterium tuberculosis
pulmonary tuberculosis
tyrosine kinase